The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

septrx.com

Stage

Series A | Alive

Total Raised

$2.7M

Last Raised

$2.7M | 11 yrs ago

About SeptRx

SeptRx is a cardiovascular medical device company that is developing a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale.

SeptRx Headquarter Location

Fremont, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

SeptRx Patents

SeptRx has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/19/2005

6/24/2014

Congenital heart defects, Androgens and anabolic steroids, Theraphosidae, Androstanes, Embryology of cardiovascular system

Grant

Application Date

7/19/2005

Grant Date

6/24/2014

Title

Related Topics

Congenital heart defects, Androgens and anabolic steroids, Theraphosidae, Androstanes, Embryology of cardiovascular system

Status

Grant

Latest SeptRx News

SeptRx Launches European Testing of New Device to Treat PFO

Jun 17, 2011

June 17th, 2011 Smit Shah Cardiac Surgery , Cardiology , Radiology SeptRx, Inc. of Fremont, CA has announced the start of the new InterSEPT clinical trial in Europe, which will provide additional safety and efficacy data about the company’s percutaneous transcatheter SeptRx Intrapocket PFO Occluder (IPO). The device is designed to repair patent foramen ovale (PFO) by bringing the septal surfaces together, without leaving much trace on both sides of the interatrial septum. The IPO device performed favorably in an initial trial, and SeptRx plans to apply for CE Mark approval following this latest trial. Some more specifics from the product page: • Unlike first generation PFO closure devices, the SeptRx® IPO directly treats the pocket of the PFO while minimizing the impact to the atrial spaces, especially minimizing the residual material in the left atrium. • The flat frame of the SeptRx® IPO applies a gentle force to the PFO tunnel to laterally stretch the tissues and flatten the pocket of the PFO to bring the septal surfaces together and trigger the body’s natural adhesion response. • The internal mesh of the SeptRx® IPO promotes permanent occlusion of the tunnel, while simultaneously providing an immediate inhibitor to the conduction of emboli. • The SeptRx® IPO is delivered via a low profile (9 Fr), over-the-wire delivery system for increased safety and ease-of-use. • The SeptRx® IPO has excellent radiopacity and is fully recapturable.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.